title: Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report.
abstract: In the current report, we describe a patient with moderate nephritis and severe skin Henoch Schönlein purpura (HSP) who has been treated with rituximab. Complete and sustained skin and renal remission resulted from the treatment. Thus, further studies are required to confirm the efficacy of rituximab as first-line treatment in HSP, and it might be an interesting new therapeutic option.
authors: Department of Nephrology, CHU St Louis, Paris, France. evangeline.pillebout@sls.aphp.fr
authors: Evangéline
authors: E
authors: Pillebout
authors: Fabiane
authors: F
authors: Rocha
authors: Laurence
authors: L
authors: Fardet
authors: Michel
authors: M
authors: Rybojad
authors: Jérôme
authors: J
authors: Verine
authors: Denis
authors: D
authors: Glotz
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D006801:Humans; D011695:IgA Vasculitis / Q000188:drug therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D056747:Immunomodulation; D008297:Male; D000069283:Rituximab; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab